Novo Nordisk Says CEO to Step Down -- Barrons.com

Dow Jones

16 May

By Elsa Ohlen

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of GLP-1 drugs Ozempic and Wegovy.

It was a "mutual agreement," Novo said in a statement Friday. The search for Fruergaard Jørgensen's successor is ongoing, the company added.

Novo Nordisk stock was up about 1.8% in Denmark. Its American depositary receipts were down 2.8% to $64.20.

This is breaking news. Check back for more analysis soon.

Write to Elsa Ohlen at elsa.ohlen@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

May 16, 2025 07:18 ET (11:18 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2535396828"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535396828\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535396828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535396828","market":"sg","top_or_hot":-1,"title":"Novo Nordisk Says CEO to Step Down -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elsa Ohlen \n</p>\n<p>\n  Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of GLP-1 drugs Ozempic and Wegovy. \n</p>\n<p>\n     It was a \"mutual agreement,\" Novo said in a statement Friday. The search for Fruergaard Jørgensen's successor is ongoing, the company added. \n</p>\n<p>\n     Novo Nordisk stock was up about 1.8% in Denmark. Its American depositary receipts were down 2.8% to $64.20. \n</p>\n<p>\n     This is breaking news. Check back for more analysis soon. \n</p>\n<p>\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 16, 2025 07:18 ET (11:18 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Says CEO to Step Down -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Says CEO to Step Down -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-16 19:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elsa Ohlen \n</p>\n<p>\n  Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of GLP-1 drugs Ozempic and Wegovy. \n</p>\n<p>\n     It was a \"mutual agreement,\" Novo said in a statement Friday. The search for Fruergaard Jørgensen's successor is ongoing, the company added. \n</p>\n<p>\n     Novo Nordisk stock was up about 1.8% in Denmark. Its American depositary receipts were down 2.8% to $64.20. \n</p>\n<p>\n     This is breaking news. Check back for more analysis soon. \n</p>\n<p>\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 16, 2025 07:18 ET (11:18 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535396828","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535396828","pubTimestamp":1747394280,"columns":[{"name":"Executive Changes","id":29,"label_key":"executive"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk CEO Lars Fruergaard Jrgensen will step down as CEO of the Danish maker of GLP-1 drugs Ozempic and Wegovy.It was a \"mutual agreement,\" Novo said in a statement Friday. The search for Fruergaard Jrgensen's successor is ongoing, the company added.Novo Nordisk stock was up about 1.8% in Denmark. Its American depositary receipts were down 2.8% to $64.20.This is breaking news. Check back for more analysis soon.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德表示首席执行官将辞职--Barrons.com","themeId":"6839c52e324857dcd0e021c7027313fa","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"By Elsa Ohlen \n\n\n  Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of GLP-1 drugs Ozempic and Wegovy. \n\n\n     It was a \"mutual agreement,\" Novo said in a statement Friday. The search for Fruergaard Jørgensen's successor is ongoing, the company added. \n\n\n     Novo Nordisk stock was up about 1.8% in Denmark. Its American depositary receipts were down 2.8% to $64.20. \n\n\n     This is breaking news. Check back for more analysis soon. \n\n\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n\n\n     This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 07:18 ET (11:18 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}